"Patient-reported outcomes in futibatinib-treated intrahepatic cholangiocarcinoma patients with fgfr2 fusions/rearrangements: results from the foenix-CCA2 study "
Authors
Bridgewater, JAHollebecque, A.
Furuse, J
Goyal, L
Meric-Bernstam, F
Epstein, R. S.
Morlock, R.
Salimi, T.
Wacheck, V.
Liu, M
Benhadji, K.
Valle, Juan W
Affiliation
UCL Cancer Institute, London, UKIssue Date
2022
Metadata
Show full item recordAbstract
We report patient-reported outcomes (PROs) results from the pivotal phase 2 trial FOENIX-CCA2 (NCT02052778). FOENIX-CCA2 evaluated futibatinib, an irreversible FGFR1–4 inhibitor, among intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements. Futibatinib demonstrated a confirmed objective response rate of 41.7%; adverse events were manageable. PROs were a prespecified secondary objective of the study.Citation
Bridgewater, J A, Hollebecque, A, Furuse, J, Goyal, L, Meric-Bernstam, F, Epstein, R S, Morlock, R, Salimi, T, Wacheck, V, Liu, M, Benhadji, K, Valle, Juan W. "Patient-reported outcomes in futibatinib-treated intrahepatic cholangiocarcinoma patients with fgfr2 fusions/rearrangements: results from the foenix-CCA2 study. Value in Health . 2022Journal
Value in HealthDOI
10.1016/j.jval.2021.11.1065Additional Links
https://dx.doi.org/10.1016/j.jval.2021.11.1065Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jval.2021.11.1065